158 related articles for article (PubMed ID: 17993233)
1. p53, BRCA1 and breast Cancer chemoresistance.
Scata KA; El-Deiry WS
Adv Exp Med Biol; 2007; 608():70-86. PubMed ID: 17993233
[TBL] [Abstract][Full Text] [Related]
2. Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Drost R; Jonkers J
Oncogene; 2014 Jul; 33(29):3753-63. PubMed ID: 23955079
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.
Hartman AR; Ford JM
Nat Genet; 2002 Sep; 32(1):180-4. PubMed ID: 12195423
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of repair genes by BRCA1.
El-Deiry WS
Cancer Biol Ther; 2002; 1(5):490-1. PubMed ID: 12496474
[TBL] [Abstract][Full Text] [Related]
5. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair.
Brugarolas J; Jacks T
Nat Med; 1997 Jul; 3(7):721-2. PubMed ID: 9212093
[No Abstract] [Full Text] [Related]
6. BRCA1: a scaffold for p53 response?
Hohenstein P; Giles RH
Trends Genet; 2003 Sep; 19(9):489-94. PubMed ID: 12957542
[No Abstract] [Full Text] [Related]
7. Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers.
Navaraj A; Mori T; El-Deiry WS
Cancer Biol Ther; 2005 Dec; 4(12):1409-14. PubMed ID: 16357511
[TBL] [Abstract][Full Text] [Related]
8. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
9. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
10. Mammary tumor formation in p53- and BRCA1-deficient mice.
Cressman VL; Backlund DC; Hicks EM; Gowen LC; Godfrey V; Koller BH
Cell Growth Differ; 1999 Jan; 10(1):1-10. PubMed ID: 9950212
[TBL] [Abstract][Full Text] [Related]
11. Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers.
Miyoshi Y; Iwao K; Takahashi Y; Egawa C; Noguchi S
Cancer Lett; 2000 Oct; 159(2):211-6. PubMed ID: 10996734
[TBL] [Abstract][Full Text] [Related]
12. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
[TBL] [Abstract][Full Text] [Related]
15. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?
Martin AM; Kanetsky PA; Amirimani B; Colligon TA; Athanasiadis G; Shih HA; Gerrero MR; Calzone K; Rebbeck TR; Weber BL
J Med Genet; 2003 Apr; 40(4):e34. PubMed ID: 12676907
[No Abstract] [Full Text] [Related]
16. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.
Santarpia M; Altavilla G; Margeli M; Cirauqui B; Mesiti M; Cavallari V; Ramirez JL; Sanchez-Ronco M; Santarpia L; Taron M; Rosell R
Cancer Invest; 2008 Dec; 26(10):1044-51. PubMed ID: 18798071
[TBL] [Abstract][Full Text] [Related]
18. P53 and its molecular basis to chemoresistance in breast cancer.
Knappskog S; Lønning PE
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S23-30. PubMed ID: 22313396
[TBL] [Abstract][Full Text] [Related]
19. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
20. BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?
Mullan PB; Gorski JJ; Harkin DP
Biochim Biophys Acta; 2006 Dec; 1766(2):205-16. PubMed ID: 16919882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
